The chronic inflammatory state in our patients, together with the increase in ADA values in TDF-treated patients, may provide evidence of how one of the main comorbidities of HIV infection, decreased bone mineral density (BMD), could be regulated by tenofovir in early stages of antiretroviral therapy [53]. This evidence concerns the gene ADA and HIV infectious disease.